Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.75
-5% vs avg
5yr avg: 0.79
30Y Low0.4·High56.7
ROE
↑
-54.2%
↓+58% vs avg
5yr avg: -128.9%
30Y Low-433%·High-54%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CRBP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Corbus Pharmaceuticals Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $104M | $108M | $129M | $26M | $14M | $76M | $98M | $349M | $333M | $356M | $348M |
| Enterprise Value | $77M | $82M | $115M | $33M | $22M | $77M | $39M | $327M | $292M | $294M | $333M |
| P/E Ratio → | -1.41 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 85.93 | 24.81 | 9.65 | 69.03 | 146.00 | 181.86 |
| P/B Ratio | 0.75 | 0.73 | 0.90 | — | 0.42 | 1.10 | 2.16 | 56.66 | 12.09 | 6.17 | 38.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CRBP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 87.72 | 9.92 | 9.04 | 60.45 | 120.50 | 174.16 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CRBP Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -54.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | -85.9% | 100.0% | -147.9% | -908.1% | -967.1% | -707.6% |
| Operating Margin | — | — | — | — | — | -6350.1% | -3119.2% | -213.3% | -1176.8% | -1334.4% | -1045.6% |
| Net Profit Margin | — | — | — | — | — | -5166.4% | -2826.1% | -197.7% | -1154.5% | -1328.6% | -1046.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.2% | -54.2% | -59.3% | -342.0% | -109.4% | -79.6% | -432.7% | -424.3% | -130.5% | -97.2% | -223.4% |
| ROA | -48.5% | -48.5% | -43.7% | -94.3% | -64.2% | -43.4% | -147.0% | -148.7% | -97.7% | -76.4% | -130.0% |
| ROIC | -51.4% | -51.4% | -56.8% | -163.6% | -46.8% | -146.4% | — | — | — | — | — |
| ROCE | -58.5% | -58.5% | -69.4% | -180.1% | -48.3% | -69.5% | -290.2% | -357.3% | -129.5% | -96.1% | -219.2% |
CRBP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $28M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | — | 0.76 | 0.38 | 0.59 | 1.53 | 0.01 | 0.01 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.18 | -0.10 | — | 0.25 | 0.02 | -1.29 | -3.62 | -1.50 | -1.08 | -1.65 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -20.48 | -13.94 | -18.86 | -30.59 | -119.42 | — | — | — | — |
Net cash position: cash ($28M) exceeds total debt ($2M)
CRBP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Corbus Pharmaceuticals Holdings, Inc.'s current ratio of 8.07x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.74x to 8.07x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.07 | 8.07 | 12.94 | 0.74 | 4.76 | 5.89 | 2.89 | 1.09 | 2.45 | 7.98 | 1.96 |
| Quick Ratio | 8.07 | 8.07 | 12.94 | 0.74 | 4.76 | 5.89 | 2.88 | 1.17 | 2.45 | 7.98 | 1.96 |
| Cash Ratio | 7.89 | 7.89 | 12.61 | 0.66 | 4.68 | 5.74 | 2.68 | 0.91 | 2.31 | 7.62 | 1.68 |
| Asset Turnover | — | — | — | — | — | 0.01 | 0.04 | 0.74 | 0.10 | 0.04 | 0.11 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 999999.00 |
| Days Sales Outstanding | — | — | — | — | — | — | 239.02 | 27.07 | — | — | 254.05 |
CRBP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Corbus Pharmaceuticals Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $13M | $11M | $4M | $4M | $4M | $3M | $2M | $2M | $2M | $1M |
Peer Comparison
Compare CRBP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CRBPYou | $104M | -1.4 | — | — | — | — | -54.2% | -51.4% | — |
 AGIO | $2B | -4.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 RCUS | $3B | -8.3 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $8B | -13.8 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -205.1 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 ABBV | $407B | 97.1 | 16.7 | 22.8 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 REGN | $64B | 14.8 | 15.3 | 15.6 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 INCY | $21B | 16.2 | 12.3 | 15.3 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 ARDX | $2B | -24.5 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 HALO | $8B | 26.9 | 11.3 | 12.7 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CRBP — Frequently Asked Questions
Quick answers to the most common questions about buying CRBP stock.
What is Corbus Pharmaceuticals Holdings, Inc.'s P/E ratio?
Corbus Pharmaceuticals Holdings, Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
What is Corbus Pharmaceuticals Holdings, Inc.'s ROE?
Corbus Pharmaceuticals Holdings, Inc.'s return on equity (ROE) is -54.2%. The historical average is -183.0%.
Is CRBP stock overvalued?
Based on historical data, Corbus Pharmaceuticals Holdings, Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.